Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough
Genomic profiling has revolutionized treatment options for patients with oncogene-driven cancers, such as epidermal growth factor receptor (EGFR) mutant carcinoma. Rearranged during transfection (RET) rearrangement, as one of the main activated oncogenes, has been well studied and found to be involv...
Main Authors: | SiJie Ding, Rong Wang, ShunLi Peng, Xiaoqing Luo, LongHui Zhong, Hong Yang, YueYun Ma, ShiYu Chen, Wei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220310933 |
Similar Items
-
GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential
by: Lois M. Mulligan
Published: (2019-01-01) -
RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma (PTC)
by: Cristina eRomei, et al.
Published: (2012-04-01) -
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
by: Shinkichi Takamori, et al.
Published: (2021-08-01) -
Significances of RET Fusion Gene in Non-small Cell Lung Cancer
by: Jingjing LIU, et al.
Published: (2013-11-01) -
Germline mutation of exon 19 of RET proto-oncogene in an Iranian population with Medullary thyroid cancer
by: Hoda Golab Ghadaksaz, et al.
Published: (2015-09-01)